Thomas George Larson

Array ( [id] => 1577514 [patent_doc_number] => 06448009 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-09-10 [patent_title] => 'Method for target site selection and discovery' [patent_app_type] => B1 [patent_app_number] => 09/676807 [patent_app_country] => US [patent_app_date] => 2000-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 16080 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/448/06448009.pdf [firstpage_image] =>[orig_patent_app_number] => 09676807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4393562 [patent_doc_number] => 06297031 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-10-02 [patent_title] => 'Escherichia coli strain and method for producing L-threonine' [patent_app_type] => 1 [patent_app_number] => 9/598451 [patent_app_country] => US [patent_app_date] => 2000-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2429 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/297/06297031.pdf [firstpage_image] =>[orig_patent_app_number] => 598451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4339054 [patent_doc_number] => 06333404 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-12-25 [patent_title] => 'Human nucleosome assembly protein gene' [patent_app_type] => 1 [patent_app_number] => 9/565538 [patent_app_country] => US [patent_app_date] => 2000-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 50155 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/333/06333404.pdf [firstpage_image] =>[orig_patent_app_number] => 565538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4265395 [patent_doc_number] => 06322727 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-27 [patent_title] => 'Kit for conducting an assay to detect a substance using enzymatically-induced decomposition of dioxetanes' [patent_app_type] => 1 [patent_app_number] => 9/537693 [patent_app_country] => US [patent_app_date] => 2000-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3966 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/322/06322727.pdf [firstpage_image] =>[orig_patent_app_number] => 537693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1459089 [patent_doc_number] => 06391636 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-05-21 [patent_title] => 'Antisense oligonucleotide modulation of raf gene expression' [patent_app_type] => B1 [patent_app_number] => 09/462261 [patent_app_country] => US [patent_app_date] => 2000-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11164 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/391/06391636.pdf [firstpage_image] =>[orig_patent_app_number] => 09462261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1586005 [patent_doc_number] => 06358932 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-03-19 [patent_title] => 'Antisense oligonucleotide inhibition of raf gene expression' [patent_app_type] => B1 [patent_app_number] => 09/506790 [patent_app_country] => US [patent_app_date] => 2000-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7719 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/358/06358932.pdf [firstpage_image] =>[orig_patent_app_number] => 09506790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1532980 [patent_doc_number] => 06410518 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-06-25 [patent_title] => 'Antisense oligonucleotide inhibition of raf gene expression' [patent_app_type] => B1 [patent_app_number] => 09/506073 [patent_app_country] => US [patent_app_date] => 2000-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16734 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/410/06410518.pdf [firstpage_image] =>[orig_patent_app_number] => 09506073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7636701 [patent_doc_number] => 06379954 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-30 [patent_title] => 'Amido and peptido modified catalytic oligonucleotides' [patent_app_type] => B1 [patent_app_number] => 09/494722 [patent_app_country] => US [patent_app_date] => 2000-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 5132 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/379/06379954.pdf [firstpage_image] =>[orig_patent_app_number] => 09494722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4309338 [patent_doc_number] => 06316259 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-13 [patent_title] => 'Antisense inhibition of glycogen synthase kinase 3 alpha expression' [patent_app_type] => 1 [patent_app_number] => 9/488856 [patent_app_country] => US [patent_app_date] => 2000-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30736 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/316/06316259.pdf [firstpage_image] =>[orig_patent_app_number] => 488856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4367845 [patent_doc_number] => 06287860 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-09-11 [patent_title] => 'Antisense inhibition of MEKK2 expression' [patent_app_type] => 1 [patent_app_number] => 9/488744 [patent_app_country] => US [patent_app_date] => 2000-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29255 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/287/06287860.pdf [firstpage_image] =>[orig_patent_app_number] => 488744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4407619 [patent_doc_number] => 06265216 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-07-24 [patent_title] => 'Antisense modulation of cot oncogene expression' [patent_app_type] => 1 [patent_app_number] => 9/489868 [patent_app_country] => US [patent_app_date] => 2000-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28619 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/265/06265216.pdf [firstpage_image] =>[orig_patent_app_number] => 489868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4270178 [patent_doc_number] => 06323029 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-27 [patent_title] => 'Antisense modulation of glycogen synthase kinase 3 beta expression' [patent_app_type] => 1 [patent_app_number] => 9/489765 [patent_app_country] => US [patent_app_date] => 2000-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28670 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/323/06323029.pdf [firstpage_image] =>[orig_patent_app_number] => 489765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4407501 [patent_doc_number] => 06300132 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-10-09 [patent_title] => 'Antisense inhibition of telomeric repeat binding factor 2 expression' [patent_app_type] => 1 [patent_app_number] => 9/467642 [patent_app_country] => US [patent_app_date] => 1999-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28612 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/300/06300132.pdf [firstpage_image] =>[orig_patent_app_number] => 467642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4302752 [patent_doc_number] => 06326199 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-12-04 [patent_title] => 'Gapped 2\' modified oligonucleotides' [patent_app_type] => 1 [patent_app_number] => 9/453514 [patent_app_country] => US [patent_app_date] => 1999-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 14320 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/326/06326199.pdf [firstpage_image] =>[orig_patent_app_number] => 453514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4403967 [patent_doc_number] => 06271029 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-08-07 [patent_title] => 'Antisense inhibition of cytohesin-2 expression' [patent_app_type] => 1 [patent_app_number] => 9/428583 [patent_app_country] => US [patent_app_date] => 1999-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28426 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/271/06271029.pdf [firstpage_image] =>[orig_patent_app_number] => 428583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4379792 [patent_doc_number] => 06303582 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-10-16 [patent_title] => 'Compositions and methods for nucleic acid delivery to the lung' [patent_app_type] => 1 [patent_app_number] => 9/427836 [patent_app_country] => US [patent_app_date] => 1999-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7260 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/303/06303582.pdf [firstpage_image] =>[orig_patent_app_number] => 427836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1543023 [patent_doc_number] => 06372721 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-16 [patent_title] => 'Method for inducing DNA synthesis in neurons' [patent_app_type] => B1 [patent_app_number] => 09/408508 [patent_app_country] => US [patent_app_date] => 1999-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 15360 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/372/06372721.pdf [firstpage_image] =>[orig_patent_app_number] => 09408508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4317134 [patent_doc_number] => 06248532 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-06-19 [patent_title] => 'Creba isoform' [patent_app_type] => 1 [patent_app_number] => 9/407715 [patent_app_country] => US [patent_app_date] => 1999-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10065 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/248/06248532.pdf [firstpage_image] =>[orig_patent_app_number] => 407715 [rel_patent_id] =>[rel_patent_doc_number] =>)